TATVANSETATVA CHIN PHARM CHEM LTDHighNeutral
Announced Fri, 17 Jul · 15:46 IST

Tatva Chintan Q1 PAT doubles; board clears Rs 200 Cr Dahej expansion

Revenue Growth 20pctPat Growth 25pctResults View source PDF

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+18.3%1-day move
₹1430.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+18.3+16.2+19.6+20.2+27.1
Up moveDown movePending
AI summary

Consolidated revenue up 25% YoY to Rs 1,670 million; PAT doubled to Rs 160 million. Standalone revenue grew 34% to Rs 1,467 million, PAT at Rs 104 million. Board approved Dahej-III greenfield unit with 344 KL reactor capacity, Rs 200 Cr investment over 21 months. Borrowing limit proposed to rise from Rs 300 Cr to Rs 1,000 Cr. Re-appointed Managing Director and two whole-time directors for 3 years. Statutory auditors gave unmodified review opinion.

Likely market impact

Strong Q1 earnings growth signals recovery; capacity expansion shows growth intent but 3x jump in debt limit may raise concerns.